This result is in contrast with findings from a recent Cochrane systematic review on the clinical impact of CSF t-tau and p-tau for the diagnosis of Alzheimer’s and other dementias in people with mild cognitive impairment (MCI), which reported that the classical AD biomarkers showed better potential in ruling out AD rather than in ruling in [5]. The gene discussed is MAPT; the disease is Alzheimer disease.